BMS-986365 is a novel, orally bioavailable androgen receptor ligand-directed degrader with a dual mechanism of action, degrading and competitively inhibiting the androgen receptor.
BridgeBio's BBO-8520 is a selective, covalent KRAS(G12C) inhibitor designed to target the 'ON' state of the protein, potentially enhancing clinical efficacy.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.